Has the FDA issued warning letters about 7-OH?

Yes. The FDA has issued multiple warning letters to companies marketing 7-hydroxymitragynine-containing products. Common citations include marketing as unapproved new drugs, illegal use as a food additive, and adulteration of products labeled as dietary supplements.

What happens if a warning letter is ignored?

Recipients who fail to respond adequately can face escalating enforcement, including product seizure, court injunction, civil money penalties, and in some cases criminal prosecution. The warning letter typically specifies a 15-working-day response window.

Where can I read FDA warning letters?

All FDA warning letters are public and indexed on the FDA website at www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.

What is a close-out letter?

A close-out letter is issued when the FDA has determined that the violations cited in a prior warning letter have been corrected. It does not erase the underlying warning but documents resolution.

Regulatory & Compliance

FDA Warning Letter

At-a-glance comparison

Spec	Value
Issuing authority	U.S. Food and Drug Administration (FDA)
Statutory basis	Federal Food, Drug, and Cosmetic Act (FD&C Act)
Type of action	Formal notification of regulatory violation; not a final agency action
Standard response window	Typically 15 working days for the recipient to respond in writing
Public availability	All warning letters are public and indexed on www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
Common 7-OH-specific citations	Marketing of 7-OH products as unapproved new drugs (FD&C Act §505); illegal addition of 7-OH to food (§409); adulteration of dietary supplements (§402)
What follows non-compliance	Possible escalation to product seizure, injunction, or criminal prosecution

What is an FDA warning letter?

An FDA warning letter is a formal written notification from the U.S. Food and Drug Administration to a regulated entity (a manufacturer, distributor, importer, or marketer) identifying specific violations of the Federal Food, Drug, and Cosmetic Act and requiring the recipient to undertake corrective action. The letter typically specifies the violations, cites the relevant statutory and regulatory provisions, requires a written response within a defined timeframe (most commonly 15 working days), and warns of potential further enforcement action if the violations are not corrected.

Warning letters are not final agency actions and do not impose penalties; they are notifications that put the recipient on notice of FDA's position. However, recipients who fail to respond adequately can face escalating enforcement, including product seizure, injunction, civil money penalties, and in some cases criminal prosecution. All FDA warning letters are public and are indexed on the FDA's website.

FDA warning letters concerning 7-hydroxymitragynine products

The FDA has issued multiple warning letters to companies marketing 7-OH-containing products. The letters typically cite three categories of violations. First, the marketing of products with health-claim language as unapproved new drugs under FD&C Act § 505, meaning a product whose labeled or promoted use makes it a drug under the Act, but which has not gone through the FDA's drug-approval process. Second, the use of 7-OH as a food additive without an approved food-additive regulation, in violation of § 409. Third, the marketing of 7-OH products as dietary supplements when the FDA has stated 7-OH does not qualify as a dietary ingredient, making such products adulterated under § 402.

These warning letters preceded and informed the FDA's July 2025 recommendation that the U.S. Drug Enforcement Administration place 7-hydroxymitragynine in Schedule I of the Controlled Substances Act. The dedicated FDA Position glossary entry covers the broader regulatory posture in more depth.

How to read and verify a warning letter

Every warning letter on the FDA website includes the recipient name, the date issued, the FDA office that issued it, the specific products and labeling at issue, the citations of relevant FD&C Act provisions, the required corrective actions, and the response deadline. Subsequent close-out letters are issued when the FDA has determined that the cited violations have been corrected; a close-out letter does not erase the underlying warning but documents resolution.

Warning letters are useful tools for assessing the regulatory history of a manufacturer or distributor in the kratom alkaloid space. A search of the FDA warning-letter database with a vendor name or product line surfaces all public letters; absence of a letter is not proof of compliance, but presence of unresolved letters is a meaningful signal.

Common questions about fda warning letter

What is an FDA warning letter?: A formal written notification from the FDA to a regulated entity identifying violations of the Federal Food, Drug, and Cosmetic Act and requiring corrective action. Warning letters are public and indexed on the FDA website.
Has the FDA issued warning letters about 7-OH?: Yes. The FDA has issued multiple warning letters to companies marketing 7-hydroxymitragynine-containing products. Common citations include marketing as unapproved new drugs, illegal use as a food additive, and adulteration of products labeled as dietary supplements.
What happens if a warning letter is ignored?: Recipients who fail to respond adequately can face escalating enforcement, including product seizure, court injunction, civil money penalties, and in some cases criminal prosecution. The warning letter typically specifies a 15-working-day response window.
Where can I read FDA warning letters?: All FDA warning letters are public and indexed on the FDA website at www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.
What is a close-out letter?: A close-out letter is issued when the FDA has determined that the violations cited in a prior warning letter have been corrected. It does not erase the underlying warning but documents resolution.

References

U.S. Food and Drug Administration. Warning Letters database. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 301 et seq.
U.S. Food and Drug Administration. (2025, July). Recommendation to schedule 7-hydroxymitragynine.
U.S. Food and Drug Administration. Regulatory Procedures Manual, Chapter 4 - Advisory Actions.

Important safety information:

Products containing 7-hydroxymitragynine (7-OH) are sold for adult use only (21+). These statements have not been evaluated by the U.S. Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. The FDA has raised safety concerns regarding concentrated 7-OH products; consult a qualified healthcare professional before use. Do not operate vehicles or machinery after use. Keep out of reach of children and pets. Laws vary by state, buyers are responsible for knowing applicable law.

Oops, your cart is still empty